Vous êtes sur le point de quitter Medscape Education.
AnnulerContinuer
 

CPD

CAR T-Cell Therapy in Non-Hodgkin Lymphoma and Multiple Myeloma: A Clinical Update

  • Authors: Gilles Salles, MD, PhD; Jeremy Abramson, MD; Noopur Raje, MD; Hermann Einsele, MD, PhD
  • CPD Released: 3/21/2020
  • Valid for credit through: 3/21/2021
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematology/oncology specialists, emergency medicine physicians, and primary care physicians.

The goal of this activity is to increase awareness of the biological rational for chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), available evidence, as well as the available and emerging use of CAR T-cell therapy in real-world practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Biological rationale for CAR T-cell therapy
    • Available and emerging CAR T-cell therapies in NHL, evidence and clinical application
    • Status of development of CAR T-cell therapy in MM and implications


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Gilles Salles, MD, PhD

    Professor of Medicine
    University Claude Bernard of Lyon
    Chair
    Hematology Department
    Lyon University Hospital
    Lyon, France

    Disclosures

    Disclosure: Gilles Salles, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Abbvie; Autolus; Celgene; Gilead; Epizyme; Janssen; Karyopharm; Kite; Merck; Morphosys; Novartis; Roche; Servier; Takeda
    Served as a speaker or a member of a speakers bureau for: Abbvie; Amgen; Celgene; Gilead; Janssen; Kite; Morphosys; Novartis; Roche; Servier; Takeda

  • Jeremy Abramson, MD

    Associate Professor of Medicine
    Harvard Medical School
    Director
    Center for Lymphoma
    Massachusetts General Hospital
    Boston, Massachusetts, United States

    Disclosures

    Disclosure: Jeremy Abramson, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Abbvie; Celgene; EMD Serono; Genentech/Roche; Kite Pharma; Morphosys; Novartis
    Served as a speaker or a member of a speakers bureau for: Celgene
    Received grants for clinical research from: Celgene; Seattle Genetics

  • Noopur Raje, MD

    Director
    Center for Myeloma
    Massachusetts General Hospital
    Boston, Massachusetts, United States

    Disclosures

    Disclosure: Noopur Raje, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda
    Received grants for clinical research from: Bluebird

  • Hermann Einsele, MD, FRCP

    Professor, Director
    University Hospital Wuerzburg
    Wuerzburg, Germany

    Disclosures

    Disclosure: Hermann Einsele, MD, FRCP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda
    Served as a speaker or a member of a speakers bureau for: Amgen; Celgene; Takeda
    Received grants for clinical research from: Amgen; Celgene; Takeda

Editor

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships

Content Reviewer

  • Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships. 


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

CAR T-Cell Therapy in Non-Hodgkin Lymphoma and Multiple Myeloma: A Clinical Update

Authors: Gilles Salles, MD, PhD; Jeremy Abramson, MD; Noopur Raje, MD; Hermann Einsele, MD, PhDFaculty and Disclosures

CPD Released: 3/21/2020

Valid for credit through: 3/21/2021

processing....

Commentaire d'expert en français

Ce commentaire fait partie d’une activité de formation plus vaste. Après la participation, prière de retourner à  CAR T-Cell Therapy in Non-Hodgkin Lymphoma and Multiple Myeloma: A Clinical Update  pour accéder à l’ensemble du contenu de formation relié. 

« Return to: CAR T-Cell Therapy in Non-Hodgkin Lymphoma and Multiple Myeloma: A Clinical Update